Your browser is no longer supported. Please, upgrade your browser.
IOVA Iovance Biotherapeutics, Inc. daily Stock Chart
Iovance Biotherapeutics, Inc.
Index- P/E- EPS (ttm)-1.84 Insider Own0.20% Shs Outstand126.57M Perf Week-2.00%
Market Cap4.41B Forward P/E- EPS next Y-2.13 Insider Trans0.00% Shs Float101.92M Perf Month-0.58%
Income-230.20M PEG- EPS next Q-0.53 Inst Own89.60% Short Float14.37% Perf Quarter-17.38%
Sales- P/S- EPS this Y-25.10% Inst Trans-0.18% Short Ratio6.61 Perf Half Y22.61%
Book/sh1.92 P/B15.28 EPS next Y0.00% ROA-62.90% Target Price47.08 Perf Year20.05%
Cash/sh1.63 P/C17.97 EPS next 5Y- ROE-71.10% 52W Range17.67 - 41.49 Perf YTD6.00%
Dividend- P/FCF- EPS past 5Y-27.00% ROI- 52W High-29.28% Beta1.12
Dividend %- Quick Ratio6.50 Sales past 5Y- Gross Margin- 52W Low66.04% ATR1.64
Employees148 Current Ratio6.50 Sales Q/Q- Oper. Margin- RSI (14)46.06 Volatility5.14% 5.46%
OptionableYes Debt/Eq0.00 EPS Q/Q-83.70% Profit Margin- Rel Volume0.55 Prev Close28.29
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout- Avg Volume2.21M Price29.34
Recom1.70 SMA200.37% SMA50-8.75% SMA2007.47% Volume1,218,353 Change3.71%
Apr-22-20Initiated Mizuho Buy $61
Mar-04-20Initiated Barclays Overweight $45
Feb-26-20Reiterated Oppenheimer Outperform $32 → $35
Feb-26-20Reiterated H.C. Wainwright Buy $32 → $36
Dec-18-19Initiated JMP Securities Mkt Outperform $38
Oct-01-19Initiated Stifel Buy $27
Apr-29-19Initiated Piper Jaffray Overweight $20
Feb-28-19Reiterated Chardan Capital Markets Buy $30 → $20
Feb-07-19Initiated Robert W. Baird Outperform
Dec-31-18Resumed B. Riley FBR Buy $24
Jul-06-18Reiterated Chardan Capital Markets Buy
Apr-10-18Upgrade B. Riley FBR, Inc. Neutral → Buy $22
Mar-13-18Reiterated B. Riley FBR, Inc. Neutral $18.50 → $22
Feb-23-18Downgrade B. Riley FBR, Inc. Buy → Neutral $18 → $18.50
Jan-25-18Reiterated H.C. Wainwright Buy $16 → $22
Nov-01-17Reiterated B. Riley FBR, Inc. Buy $17.50 → $18
Jul-14-20 12:49PM  
Jul-01-20 07:11AM  
Jun-08-20 04:01PM  
Jun-04-20 11:31AM  
Jun-02-20 04:01PM  
Jun-01-20 09:20AM  
May-29-20 08:01AM  
May-28-20 09:30PM  
May-27-20 04:20PM  
May-13-20 05:01PM  
May-11-20 11:13PM  
May-08-20 11:46AM  
May-06-20 11:26AM  
May-05-20 04:01PM  
Apr-30-20 06:13PM  
Apr-29-20 12:01PM  
Apr-27-20 04:01PM  
Apr-17-20 08:43AM  
Apr-16-20 04:11PM  
Apr-13-20 05:14PM  
Mar-27-20 02:55PM  
Mar-11-20 09:18AM  
Mar-10-20 08:23AM  
Mar-02-20 04:01PM  
Feb-25-20 05:46PM  
Feb-19-20 07:00AM  
Feb-12-20 07:00AM  
Jan-15-20 08:00AM  
Jan-13-20 04:15PM  
Jan-12-20 04:30PM  
Dec-26-19 11:25AM  
Dec-23-19 05:40AM  
Dec-16-19 03:55PM  
Dec-04-19 08:03PM  
Dec-02-19 07:00AM  
Nov-21-19 07:00AM  
Nov-08-19 02:58PM  
Nov-07-19 04:32PM  
Nov-04-19 04:01PM  
Oct-31-19 04:43PM  
Oct-21-19 10:55AM  
Oct-02-19 07:00AM  
Oct-01-19 01:48PM  
Sep-27-19 04:30PM  
Sep-19-19 02:07PM  
Sep-16-19 12:00PM  
Aug-27-19 04:57PM  
Aug-26-19 04:30PM  
Aug-14-19 01:04PM  
Aug-02-19 10:24PM  
Aug-01-19 04:01PM  
Jul-29-19 03:00PM  
Jul-26-19 07:00AM  
Jul-18-19 08:00AM  
Jul-10-19 12:46PM  
Jul-08-19 06:22PM  
Jul-02-19 08:50AM  
Jun-25-19 09:21AM  
Jun-24-19 03:00PM  
Jun-19-19 01:58PM  
Jun-18-19 09:51AM  
Jun-17-19 03:37PM  
Jun-14-19 09:08AM  
Jun-12-19 10:30AM  
Jun-11-19 07:00AM  
Jun-05-19 03:11PM  
Jun-03-19 04:21PM  
May-31-19 07:00AM  
May-29-19 08:00AM  
May-23-19 04:09PM  
May-22-19 10:24AM  
May-19-19 09:00AM  
May-16-19 04:29PM  
May-15-19 05:27PM  
May-08-19 05:23AM  
May-07-19 05:13PM  
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidates include lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma; and LN-145 for the treatment of metastatic cervical cancer. It is also developing tumor infiltrating lymphocytes (TIL) and peripheral blood lymphocyte therapies for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer, and chronic lymphocytic leukemia through its sponsored trials, as well as in other oncology indications through collaborations. Iovance Biotherapeutics, Inc. has collaboration agreements with Moffitt, M.D. Anderson Cancer Center, Ohio State University, and MedImmune; and research collaboration with Cellectis S.A. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.